These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 14383121)

  • 21. Evaluation of TACE as a therapeutic agent in prostatic carcinoma.
    O'CONOR VJ; SOKOL JK
    Q Bull Northwest Univ Med Sch; 1952; 26(2):161-2. PubMed ID: 14930215
    [No Abstract]   [Full Text] [Related]  

  • 22. Managing prostate cancer.
    Gillmore R
    Practitioner; 2004 Apr; 248(1657):274-80. PubMed ID: 15114817
    [No Abstract]   [Full Text] [Related]  

  • 23. Androgens and the molecular epidemiology of prostate cancer.
    Chu LW; Reichardt JK; Hsing AW
    Curr Opin Endocrinol Diabetes Obes; 2008 Jun; 15(3):261-70. PubMed ID: 18438175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical results of the treatment of prostatic carcinoma over a ten-year period.
    STAUBITZ WJ; OBERKIRCHER OJ; LENT MH
    J Urol; 1954 Nov; 72(5):939-45. PubMed ID: 13212905
    [No Abstract]   [Full Text] [Related]  

  • 25. Is dehydroepiandrosterone a hormone?
    Labrie F; Luu-The V; Bélanger A; Lin SX; Simard J; Pelletier G; Labrie C
    J Endocrinol; 2005 Nov; 187(2):169-96. PubMed ID: 16293766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GREB1 is a novel androgen-regulated gene required for prostate cancer growth.
    Rae JM; Johnson MD; Cordero KE; Scheys JO; Larios JM; Gottardis MM; Pienta KJ; Lippman ME
    Prostate; 2006 Jun; 66(8):886-94. PubMed ID: 16496412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Therapy of malignant tumors with sex hormones, with special reference of the treatment of mammary carcinoma with androgens].
    BRAUN H; LEGLER H
    Strahlentherapie; 1954; 93(4):490-508. PubMed ID: 13187128
    [No Abstract]   [Full Text] [Related]  

  • 28. The significance of key regulators of apoptosis in the development and prognosis of prostate carcinoma. I. Proteins of the Bcl-2 family and protein p53.
    Knillová J; Kolár Z
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2003 Nov; 147(1):3-10. PubMed ID: 15034599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hormone treatment for prostate cancer: current issues and future directions.
    Ichikawa T; Suzuki H; Ueda T; Komiya A; Imamoto T; Kojima S
    Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():58-63. PubMed ID: 16273367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer.
    Nishiyama T; Hashimoto Y; Takahashi K
    Clin Cancer Res; 2004 Nov; 10(21):7121-6. PubMed ID: 15534082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN; Schröder FH
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 5alpha-reductase isozymes and androgen actions in the prostate.
    Zhu YS; Imperato-McGinley JL
    Ann N Y Acad Sci; 2009 Feb; 1155():43-56. PubMed ID: 19250191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Management of metastatic androgeno-independent prostate cancer].
    Lebret T; Méjean A
    Prog Urol; 2008 Nov; 18 Suppl 7():S343-8. PubMed ID: 19070814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparative studies of the expression of estrogen receptor-alpha and estrogen receptor-beta in prostatic carcinoma].
    Yang GS; Chen ZD
    Zhonghua Wai Ke Za Zhi; 2004 Sep; 42(18):1111-5. PubMed ID: 15498298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations.
    Morales A; Black AM; Emerson LE
    BJU Int; 2009 Jan; 103(1):62-4. PubMed ID: 18671790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estrogen action on the prostate gland: a critical mix of endocrine and paracrine signaling.
    Risbridger GP; Ellem SJ; McPherson SJ
    J Mol Endocrinol; 2007 Sep; 39(3):183-8. PubMed ID: 17766643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Testosterone replacement therapy after primary treatment for prostate cancer.
    Agarwal PK; Oefelein MG
    J Urol; 2005 Feb; 173(2):533-6. PubMed ID: 15643240
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of androgen supplementation therapy on the prostate.
    Kaufman JM
    Aging Male; 2003 Sep; 6(3):166-74. PubMed ID: 14628497
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Theoretical presuppositions and clinical findings on the use of bi-sexual steroids in prostatic adenoma; preliminary note].
    CORRADO F
    Minerva Urol; 1958; 10(2):38-40. PubMed ID: 13552454
    [No Abstract]   [Full Text] [Related]  

  • 40. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma.
    Fung KM; Samara EN; Wong C; Metwalli A; Krlin R; Bane B; Liu CZ; Yang JT; Pitha JV; Culkin DJ; Kropp BP; Penning TM; Lin HK
    Endocr Relat Cancer; 2006 Mar; 13(1):169-80. PubMed ID: 16601286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.